Posted by Michael Wonder on 17 Dec 2024
Johnson & Johnson submits application seeking US FDA approval of Simponi (golimumab) for the treatment of paediatric ulcerative colitis
16 December 2024 - Submission aims to expand Simponi ulcerative colitis indication to include paediatric population.
Johnson & Johnson today announced the submission of a supplemental biologics license application to the US FDA seeking expanded approval of Simponi (golimumab) for the treatment of children two years and older with moderately to severely active ulcerative colitis.
